INTRODUCTION
Portal hypertensive gastropathy (PHG) is an endoscopic abnormality of the gastric mucosa that is most commonly obThis is publication #12 from the HALT-C Trial Group. served in patients with advanced liver disease and/or portal hypertension (1, 2) . This endoscopic lesion is characterized by the presence of a mucosal mosaic pattern with a snake skin-like appearance, focal red and brown spots, and vascular ectasias localized to the fundus or body of the stomach 984 Fontana et al. (2) (3) (4) (5) . The severity of PHG is commonly graded as mild or severe but the condition is very dynamic and some patients spontaneously improve while others worsen despite no apparent change in liver disease status (4) (5) (6) (7) . Ligation of varices and sclerotherapy have been associated with the development of de novo PHG in up to 50% of patients during short-term follow-up (8, 9) . Patients with PHG are at increased risk of acute as well as chronic gastrointestinal bleeding although the annual incidence of bleeding has been difficult to quantify and distinguish from that due to esophagogastric varices (6, 7, 10) .
Prior studies have suggested that PHG is more common in patients with decompensated cirrhosis compared to those with compensated liver disease (2, 6, 11) . However, most of these studies were of limited size and included patients with varying etiologies of liver disease (2, 6) . The aim of the current study was to determine the prevalence of PHG in a large cohort of well-characterized patients with chronic hepatitis C and biopsy proven bridging fibrosis or cirrhosis who were enrolled in the Hepatitis C Antiviral Longterm Treatment against Cirrhosis trial (HALT-C). In addition, we set out to identify baseline laboratory and clinical features associated with the presence and severity of PHG. Finally, we determined the relationship between esophageal varices and PHG in this large cohort of patients without a history of prior gastrointestinal bleeding or endoscopic therapy.
METHODS

Patient Population
This study included all patients entering the randomized phase of the HALT-C trial who underwent a screening esophagogastroduodenoscopy (EGD). Before enrollment, all subjects signed a written informed consent that had been approved by the local Institutional Review Boards at each of the 10 participating sites (12) . The data were analyzed at the data coordinating center (New England Research Institute, Boston, MA). The entry and exclusion criteria for the HALT-C trial have been previously published (12, 13) . Briefly, all HALT-C patients had detectable hepatitis C virus (HCV) RNA, a liver biopsy within 12 months of entry demonstrating an Ishak fibrosis score of 3 or 4 (bridging fibrosis) or 5-6 (cirrhosis), and nonresponse to prior interferon therapy. Subjects with a Child-Turcotte-Pugh score of >6 or a prior history of variceal/portal hypertensive bleeding, ascites, or hepatic encephalopathy were excluded. Enrolled subjects were retreated with pegylated Interferonα2a (180 μg/wk; Pegasys TM , Roche Laboratories, Nutley NJ) and ribavirin (1,000-1,200 mg daily, Copegus TM , Roche). Those with persistently detectable HCV RNA at week 20 were eligible for randomization to either pegylated Interferonα2a 90 μg/wk or observation without therapy for the next 3.5 yr. Week 20 virologic responders received a full 48-wk course of peginterferon and ribavirin. Patients with virologic breakthrough during treatment or those with relapse after week 48 were also eligible for randomization. In addition, subjects with Ishak 3-6 fibrosis who had failed to respond to at least 24 wk of pegylated interferon and ribavirin given outside of the trial, referred to as "Express" patients, were eligible for randomization.
A pretreatment medical history and physical exam was performed before enrollment. Lifetime alcohol consumption was assessed using a modified Skinner survey (14) . All liver biopsies were evaluated by a central group of pathologists and the degree of hepatic fibrosis and inflammation were defined using the Ishak scoring system (15) . Fasting insulin and glucose levels were obtained in all patients except the Express group. Insulin resistance was determined by the homeostatic model (IR HOMA ) (16) . Splenomegaly was defined as a spleen length >13 cm on sonography.
Endoscopy
The protocol for EGD including the criteria for PHG grading was written in a manual of procedures and members at all centers were trained on the PHG scoring system before study initiation. The presence and severity of PHG were scored by the local study endoscopist according to the New Italian Endoscopy Conference criteria (NIEC) on a standard form (4) . Specifically, the mucosal mosaic pattern was considered mild and scored 1 if there were diffuse pink polygonal, scalelike areas and severe with a score of 2 if present throughout the mucosa. Focal flat or slightly bulging red marks were considered mild and scored 1 if found in isolated areas and severe with a score of 2 if present throughout the mucosa. Gastric antral vascular ectasia (GAVE) was diagnosed by the presence of flat or slightly raised, red stripe-like lesions radiating from the pylorus to the antrum and body of the stomach and given a score of 2. The presence of black-brown spots representative of old submucosal hemorrhage were not recorded. A PHG score of 1-3 was considered mild PHG while a score of 4 or more was considered severe PHG (4) . The presence and size of esophageal varices were graded as small (F1) when they impinged on 25% of the lumen, medium (F2) when between F1 and F3, and large (F3) if the varices impinged on >50% of the lumen. Other findings such as the presence of a hiatal hernia, gastric ulcer, and duodenal ulcer were reported in a text field by the local endoscopist.
Statistical Analysis
Continuous variables with non-normal distribution were log transformed. Univariate analysis of demographic, liver disease, and clinical factors as correlates of the presence and severity of PHG and its component features were undertaken. In addition, multivariate logistic regression analysis with stepwise selection of significant independent predictors was performed to identify independent correlates of the presence and severity of PHG as well as GAVE.
Portal Hypertensive Gastropathy
985
RESULTS
Patient Population
A total of 1,050 subjects were enrolled in the randomized phase of the HALT-C trial of whom 1,016 (97%) underwent EGD and were included in this study ( Table 1 ). The mean age of participants was 50.2 yr, there was a preponderance of men (71%), and 18% were African American. The majority of subjects were abstinent from alcohol (86%) and cigarettes (70%) at enrollment. Forty-nine percent of subjects reported use of nonsteroidal anti-inflammatory drugs (NSAIDs) during the 12 months prior to their endoscopy while only 14% were receiving a proton pump inhibitor (PPI) and 5% a cyclo- oxygenase type 2 (COX-2) inhibitor at the time of EGD. As expected, there was an overrepresentation of HCV genotype 1 in this group of nonresponders to prior pegylated interferon and ribavirin. The mean body mass index (BMI) was 29.9 kg/m 2 and 24% of subjects were diabetic. There were 598 subjects (58%) with Ishak stage 3 or 4 fibrosis and 418 subjects (42%) with Ishak stage 5 or 6 fibrosis. The proportion of patients with diabetes mellitus, Mallory bodies on biopsy, and the mean Ishak inflammatory scores were significantly higher in subjects with cirrhosis compared to those with bridging fibrosis. Conversely, subjects with bridging fibrosis had significantly higher platelet counts and albumin levels and lower serum bilirubin, alanine and aspartate aminotransferase (ALT, AST), alkaline phosphate, and INR levels compared to subjects with cirrhosis.
Prevalence of PHG
Overall, 374 subjects (37%) had PHG identified at surveillance EGD. In the majority of cases, PHG was mild (34%) and only 29 patients (3%) had severe changes. The most frequent endoscopic feature suggestive of PHG was the presence of mucosal mosaic pattern which was seen in 33% of subjects (Fig. 1) . In contrast, isolated or confluent red marks were reported in 15% of subjects and GAVE features were noted in only 3%. If GAVE features were present, the subject was more likely to have severe PHG compared to subjects with PHG and no GAVE lesions (odds ratio = 40.4 (15.9, 101.9) p < 0.0001).
Both mild and severe PHG were significantly associated with the stage of hepatic fibrosis (Fig. 2 , p < 0.0001 for trend). The mean levels of several biochemical markers of liver disease severity (i.e., albumin, bilirubin, and INR) were also significantly worse among subjects with PHG compared to those without PHG (Table 2) . Similarly, the mean Ishak fibrosis scores and the prevalence of splenomegaly were sig- nificantly higher among those with PHG compared to those without PHG. Interestingly, Mallory bodies were more frequently noted in subjects with PHG. In addition, the IR HOMA and glucose levels were significantly higher among subjects with PHG and these differences were most pronounced in nondiabetic patients. However, the prevalence of diabetes and mean BMI levels were not significantly greater in subjects with PHG compared to subjects without PHG. PHG was less frequently identified in African American patients (35%) compared to others (39%) ( p = 0.037).
Although we had anticipated that lifetime smoking and alcohol consumption would be associated with PHG, neither of these measures showed a significant association. In addition, use of NSAIDs, PPIs, COX-2 inhibitors, and beta-blockers at the time of EGD was not associated with PHG. Finally, the mean hemoglobin levels and iron stores of subjects with PHG were not significantly different from those without PHG.
Correlates of PHG
On univariate analysis, serum alkaline phosphatase, AST/ALT ratio, splenomegaly, INR, bilirubin, log 10 IR HOMA , and log 10 glucose levels were all associated with a greater likelihood of PHG. In contrast, African American race, serum albumin, and platelet counts were associated with a lower frequency of PHG. Using stepwise logistic regression, non-African American race, albumin, platelets, bilirubin, and log 10 glucose were independently associated with PHG (Table 3) . However, the overall model c-statistic was only 0.645 and the majority of the variance was accounted for by low platelet count. Models with similar predictive ability were obtained when assessing the presence of PHG in patients with bridging fibrosis and cirrhosis separately (data not shown). Positive correlates of severe PHG in the overall cohort included AST/ALT ratio, bilirubin, Ishak fibrosis score, and log 10 glucose levels while platelet counts were negatively associated with severe PHG. Using logistic regression analysis, only log 10 glucose and total bilirubin levels were significant independent correlates of severe PHG (Table 3) .
Since GAVE features are most commonly associated with gastrointestinal bleeding, models to predict these changes were derived. On univariate analysis, smoking history, bilirubin, Ishak fibrosis score, NSAID use in the past 12 months, and log 10 glucose were positively associated with GAVE while platelet count and time from biopsy to endoscopy were negatively associated with GAVE. When using stepwise selection, we identified bilirubin, NSAID use, smoking history, and log 10 glucose as independent correlates of GAVE. However, the prevalence of GAVE in the study population was low (3%) and additional studies in patients with a higher prevalence of GAVE are needed to confirm the relatively weak associations noted.
Esophageal Varices and PHG
Previous studies have suggested a positive relationship between the presence of esophageal varices and PHG (2, 9). Studies of the HALT-C cohort have shown that 26% of patients had esophageal varices and that varices were significantly more common in subjects with cirrhosis compared to those with bridging fibrosis (39% vs 16%, p < 0.0001) (17) . For these reasons, the positive association between the presence of PHG and esophageal varices was not unexpected (Fig. 3) . A total of 40% of patients with PHG had varices compared to only 17% of subjects without PHG ( p < 0.0001). In addition, subjects with PHG were significantly more likely to have medium or large varices compared to subjects without PHG (odds ratio = 6.40 (95% CI: 3.47, 11.79), p < 0.0001).
Additional Endoscopic Findings
A hiatal hernia was identified in 162 subjects (16%), a gastric ulcer was noted in 18 subjects (1.8%), a duodenal ulcer in 16 (1.6%), and 5 of these subjects had both a gastric and a duodenal ulcer. There was a trend toward PHG being associated with the presence of a gastric ulcer and duodenal ulcer but neither trend was statistically significant. However, drinking alcohol in the past 6 months was positively associated with the presence of a gastric ulcer ( p = 0.016). Similarly, drinking alcohol in the past 6 months ( p = 0.043), NSAID use in the past 12 months ( p = 0.035), and the presence of 
DISCUSSION
The overall prevalence of PHG in this highly selected study population was 37%, a proportion which is consistent with other cross-sectional studies involving patients with advanced but compensated chronic liver disease (2, 6). The lower frequency of severe compared to mild PHG is also consistent with prior studies (2, 6, 18) . The current study also demonstrated a strong positive association between the presence of PHG and esophageal varices (Fig. 3) (2, 9) . The current study was unique in that it represents a large prospective cohort of well-characterized HCV patients who have undergone surveillance EGD. The presence and severity of PHG was graded in a standardized manner using a validated scoring system (18) . In addition, all liver biopsies were reviewed by a central group of expert hepatopathologists and all patients underwent extensive laboratory and clinical assessment upon study entry. The prevalence and correlates of PHG from this study are likely to be representative of American patients with advanced but compensated HCV who have failed to respond to pegylated interferon and ribavirin. The pathogenesis of PHG is not well understood but may be related to increased gastric mucosal blood flow mediated by activation of cytokines and growth factors (11, 19, 20) . There is no established link between Helicobacter pylori infection and the presence and severity of PHG (21, 22) . Hemodynamic studies demonstrate that the severity of portal hypertension is related to the likelihood of having severe PHG but is not the sole determinant (19, 23) . In particular, portal pressure measurements do not correlate with the presence or severity of GAVE and several authors have suggested alternative etiopathogenic mechanisms for GAVE (5, 24, 25) . A recent study demonstrated that subjects with acute heavy alcohol ingestion were more likely to have gastroduodenal erosions and ulcers that were independently associated with the presence and severity of PHG (26) . In the current study, however, no association was found between either lifetime or recent alcohol consumption and the prevalence or severity of PHG (Table 2) . This lack of association may have been due to the fact that most of the HALT-C patients (86%) were abstinent from alcohol at enrollment and the few who did consume alcohol were drinking minimally. Similarly, the current study also failed to demonstrate a relationship between NSAID and/or COX-2 inhibitor use and the presence or severity of PHG. Finally, although smoking has been associated with changes in gastric mucosal blood flow and mucosal ulceration, an association between PHG and smoking was not identified in this study cohort.
The expected associations between markers of liver disease severity and the presence and severity of PHG were identified on both univariate and multivariate analysis (Tables 2 and 3 ). In a logistic regression model, only non-African American race, low platelet count, high serum bilirubin, low serum 
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albumin, and high glucose levels were found to be independent predictors of PHG. The reduced probability of African Americans having PHG is consistent with a prior analysis of this cohort in which African Americans were significantly less likely to have esophageal varices (17) . The mechanism for a protective effect of race is not clear and the clinical significance is uncertain since PHG was identified in 35% of African Americans and 39% of non-African Americans. However, the prevalence of cirrhosis was lower (35% vs 43%, p = 0.0459) and the mean platelet counts were higher (180 vs 161 10 3 /mL, p = 0.0003) among African American compared to non-African American HALT-C patients. The association between glucose levels and the presence and severity of PHG may relate to an increased frequency of glucose intolerance and insulin resistance among HCV patients with more severe hepatic fibrosis (27) . Fibrotic remodeling of the liver can lead to reduced clearance of insulin and insulinlike growth factors with resultant splanchnic hyperinsulinemia that may stimulate hepatic stellate cells (27, 28) . Several studies have also demonstrated increased rates of fibrosis progression among HCV patients with hepatic steatosis and insulin resistance (29, 30) . Therefore, it is possible that the significant association between glucose levels and the presence and severity of PHG may reflect changes due to underlying insulin resistance but further physiologic studies are needed (31) (32) (33) (34) .
The prevalence of mild (3%) and severe (1%) GAVE was low in this highly selected patient population. This may in part be due to the predominance of men and the intentional exclusion of patients with a history of gastrointestinal bleeding or anemia at entry. In addition, only GAVE lesions localized to the antrum in a stripe-like appearance were scored while prior studies have suggested that vascular ectasias in patients with cirrhosis are more likely to be diffuse and located in the body (24, 35) . On multivariate modeling, both increased serum bilirubin and glucose levels were positively associated with the presence of GAVE as were the recent use of an NSAID and a lifetime history of smoking. It is wellknown that NSAIDs can induce gastroduodenal erosions and ulcers and that NSAID gastropathy tends to localize to the antrum possibly due to motility effects (36) . Interestingly, some studies have suggested that patients with cirrhosis and GAVE may display abnormal antral motility (37) . Although GAVE lesions represent a distinct clinicopathological entity, the positive association of NSAID use with GAVE lesions in this patient population is consistent with prior work demonstrating reduced gastric mucosal gel thickness in patients with PHG and increased susceptibility to caustic agents (38, 39) . Similarly, the well described epidemiological association between smoking and gastroduodenal ulceration may, in part, account for the positive association noted between smoking and GAVE (40) (41) (42) (43) (44) .
Identifying risk factors for bleeding from PHG is difficult due to the low rate of spontaneous bleeding from this entity (7, 18) . During longitudinal follow-up, subjects with severe PHG are more likely to bleed than subjects with mild PHG (6, 18) . In addition, HCV patients with cirrhosis and severe PHG were more likely to have a peptic ulcer compared to patients with mild PHG (22) . In the current study, however, there was no significant relationship between baseline hemoglobin or iron levels with the presence or severity of PHG or the presence of GAVE lesions (data not shown). These observations may be due, in part, to the intentional exclusion of subjects with a prior history of gastrointestinal bleeding or anemia at entry. Further study and follow-up should demonstrate whether patients with PHG and/or GAVE features are more likely to develop gastrointestinal bleeding during the randomized phase of HALT-C.
Limitations of this study included the lack of central review of endoscopic photos for PHG grading (45) . However, all endoscopists were trained on the scoring system and a standardized reporting form and manual of procedures were used at participating sites. The optimal means of scoring PHG remains controversial since few studies have demonstrated a relationship between PHG severity and the risk of gastrointestinal bleeding (2, 18, 45) . The PHG scoring system used in this study has been shown to have excellent interobserver agreement and to correlate with the risk of bleeding during short-term follow-up (18) . However, as with other proposed PHG scoring systems, there is a lower interobserver agreement on scoring the severity of PHG using the NIEC criteria. Portal hemodynamic studies were not performed in this study because of the associated risks and resources required. However, prior studies that have attempted to correlate portal hemodynamic measurements with endoscopic findings have yielded inconsistent results (11, 19) . Finally, subjects enrolled in HALT-C are not necessarily representative of HCV patients with advanced fibrosis in the general population since subjects with anemia, severe thrombocytopenia, or other contraindications to retreatment with pegylated IFN and ribavirin were excluded. In addition, subjects with a prior history of gastrointestinal bleeding, ascites, or encephalopathy were excluded. Nonetheless, this study represents the largest cohort of well-characterized American subjects with advanced but compensated HCV fibrosis who have undergone surveillance EGD.
In summary, 37% of 1,016 HCV patients with bridging fibrosis or compensated cirrhosis had evidence of PHG but only 3% had severe PHG. Independent correlates of PHG include biochemical markers of liver disease severity (low serum albumin, high bilirubin), portal hypertension (low platelet count), and markers of insulin resistance (high glucose levels). Subjects with a prior history of smoking and recent NSAID use were found to be at greatest risk of harboring GAVE but the low overall prevalence of this lesion limits the strength and implications of this finding. The clinical significance of PHG and GAVE as a source of gastrointestinal bleeding and as a potential correlate of disease progression will be tracked during the longitudinal phase of HALT-C.
